Status:
COMPLETED
Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris
Lead Sponsor:
Psoriasis Research Institute of Guangzhou
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Controlled, Two-Center, Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of TC cream In Treating Patients with Psoriasis Vulgaris
Eligibility Criteria
Inclusion
- Age of 18-70 years old. Both men and women and members of all races and ethnic groups
- Consistent with diagnostic criteria of stable phase psoriasis vulgaris and have at least two target lesions suitable for evaluation
- Women of childbearing age must be using birth control strategies defined by one of the following: 1) a barrier method (condom) and/or 2) oral contraceptives, during the 8-week study period.
- ISGA score ≥ 2 (at least mild severity)
- BSA (stable stage group): 1%≤ to ≤20%
- Signed a written informed consent document
- No additional exposure to the sun
Exclusion
- Subjects in pregnancy, preparing for pregnancy or breast feeding
- History of hyperergic or photosensitivity
- History of complicated cardiovascular diseases, cerebrovascular diseases, severe primary diseases of hepatic, kidney and hematopoietic system, or patients with psychiatric disorders
- History of photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosa
- Within 4 weeks prior to randomizations, patients have taken treatment with following approved or investigational psoriasis therapies on the target lesions:
- Topical treatments
- PUVA, UVB or Grenz ray therapy.
- Any systemic treatments other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin D analogues, hydroxycarbamide, azathioprine, methotrexate, cyclosporine, other immunosuppressant).
- Any types of other investigational therapies for psoriasis
- Within 3 months prior to randomizations, patients have taken systemic treatments with retinoids or biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab).
- Planned initiation of, or changes to, concomitant medications that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study.
- History of allergic reactions attributed to compounds of similar chemical or biologic compositions to Coumarins.
Key Trial Info
Start Date :
June 11 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT03372811
Start Date
June 11 2015
End Date
June 30 2018
Last Update
May 16 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, State University of New York, Downstate Medical Center
New York, New York, United States, 11203
2
Dermatology Associates
Seattle, Washington, United States, 98101